Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2718359 | 0.73 | L3MBTL1 (0.69) | SMN1; SMN2HTTLMNAPOLBALDH1A1 | |
| SCHEMBL8973343 | 0.72 | L3MBTL1 (0.67) | SMN1; SMN2LMNAPOLBALDH1A1MEN1 | |
| SCHEMBL8972353 | 0.72 | L3MBTL1 (0.67) | SMN1; SMN2LMNAPOLBALDH1A1MEN1 | |
| SCHEMBL8972793 | 0.72 | L3MBTL1 (0.67) | SMN1; SMN2LMNAPOLBALDH1A1MEN1 | |
| SCHEMBL7908984 | 0.72 | L3MBTL1 (0.67) | SMN1; SMN2LMNAPOLBALDH1A1MEN1 | |
| SCHEMBL8972298 | 0.72 | L3MBTL1 (0.67) | SMN1; SMN2LMNAPOLBALDH1A1MEN1 | |
| SCHEMBL474080 | 0.72 | L3MBTL1 (0.67) | SMN1; SMN2LMNAPOLBALDH1A1MEN1 | |
| SCHEMBL8971899 | 0.72 | L3MBTL1 (0.67) | SMN1; SMN2LMNAPOLBALDH1A1MEN1 | |
| SCHEMBL8971856 | 0.72 | L3MBTL1 (0.67) | SMN1; SMN2LMNAPOLBALDH1A1MEN1 | |
| SCHEMBL2982115 | 0.72 | L3MBTL1 (0.67) | SMN1; SMN2LMNAPOLBALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7674823-B2 | DNA-PK inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-03-09 | — | — | US | disclosed |
| US-20070238729-A1 | DNA-PK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-10-11 | — | — | US | disclosed |
| US-7226918-B2 | DNA-PK inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-06-05 | — | — | US | disclosed |
| US-20040192687-A1 | Dna-pk inhibitors | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192687-A1 | Dna-pk inhibitors | ATM, CHEK1, XRCC6 | SMN1; SMN2 4291/4885HTT 3741/4885LMNA 993/4885 |
| US-20070238729-A1 | DNA-PK INHIBITORS | ATM, CHEK2, CHEK1 | SMN1; SMN2 4287/4885HTT 4043/4885LMNA 806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.